Gene therapy for human colorectal carcinoma using human CEA promoter controled bacterial ADP-ribosylating toxin genes: PEA and DTA gene transfer

Table 1 In vivo growth inhibition of human carcinoma by the toxin genes transfer

Days following gene therapy	Estimated tumor weight (mg) of tumor xenograft following toxin genes transfer (-x±s, n = 7)
	LoVo (CEA/PEA)	RC9406 (CEA/PEA)	LoVo (CEA/DTA)	RC9406 (CEA/DTA)	LoVo (CMV/PEA)	RC9406 (CMV/DTA)	LoVo	RC9406	LoVo (CEA/PEA) + Ad
0	486 ± 160	472 ± 201	504 ± 232	516 ± 164	480 ± 200	496 ± 320	480 ± 190	490 ± 230	490 ± 130
7	404 ± 176	632 ± 246	480 ± 320	706 ± 240	365 ± 240	380 ± 224	680 ± 185	680 ± 210	414 ± 98
21	454 ± 201	1246 ± 212	645 ± 340	1321 ± 324	584 ± 402	638 ± 320	1386 ± 440	1206 ± 340	226 ± 63
35	758 ± 424	1840 ± 764	1084 ± 286	1986 ± 884	906 ± 327	986 ± 380	2810 ± 528	2762 ± 620	306 ± 45
		(n = 6)		(n = 6)	(n = 6)		(n = 4)	(n = 5)